BioMarin Pharmaceutical (BMRN) : $39.98 million worth of transactions were on upticks in BioMarin Pharmaceutical (BMRN), compared to $30.42 million on downticks. The ratio between the two was 1.31, whereas, the net money flow stood at a healthy $9.56 million on Tuesdays session. The consistent buying on upticks in the stock accounted for $9.89million worth of trades. The total money flow into the stock stood at $9.89 million. The bulls and the bears were in an equilibrium as the stock closed with a loss of -1.25%. The stock was trading at $87.48, with a drop of $1.11 over the previous days close. The stock recorded -4.38% for the week.
The company Insiders own 2.5% of BioMarin Pharmaceutical shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -11.8% . During last six month period, the net percent change held by insiders has seen a change of -3.94%. In an insider trading activity,The director of Biomarin Pharmaceutical Inc, Lawlis V Bryan sold 550 shares at $82.77 on June 20, 2016. The Insider selling transaction had a total value worth of $45,524. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Shares of BioMarin Pharmaceutical Inc. rose by 9.54% in the last five trading days and 7.87% for the last 4 weeks. BioMarin Pharmaceutical Inc. is up 2.92% in the last 3-month period. Year-to-Date the stock performance stands at -16.49%.
BioMarin Pharmaceutical (NASDAQ:BMRN): On Tuesdays trading session , Opening price of the stock was $88.83 with an intraday high of $89.98. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $87.43. However, the stock managed to close at $87.48, a loss of 1.25% for the day. On the previous day, the stock had closed at $88.59. The total traded volume of the day was 1,725,473 shares.
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Companys product portfolio is comprised of five approved products and multiple clinical and pre-clinical product candidates. Its approved products are Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). Vimizim received marketing approval in the United States, the European Union and subsequently in several other countries. Naglazyme received marketing approval in the United States, the European Union and subsequently in other countries. Kuvan was granted marketing approval in the United States, the European Union. Aldurazyme, which was developed in collaboration with Genzyme Corporation (Genzyme), was approved for marketing in the United States, the European Union, and subsequently in other countries. Firdapse was approved by the European Medicines Agency (EMA).